GB201013058D0 - Compounds for the treatment of clostridium difficile associated disease - Google Patents
Compounds for the treatment of clostridium difficile associated diseaseInfo
- Publication number
- GB201013058D0 GB201013058D0 GBGB1013058.1A GB201013058A GB201013058D0 GB 201013058 D0 GB201013058 D0 GB 201013058D0 GB 201013058 A GB201013058 A GB 201013058A GB 201013058 D0 GB201013058 D0 GB 201013058D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compounds
- treatment
- associated disease
- clostridium difficile
- difficile associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000193163 Clostridioides difficile Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1013058.1A GB2482501A (en) | 2010-08-04 | 2010-08-04 | Novel compounds for use in the treatment of Clostridium Difficile and associated diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1013058.1A GB2482501A (en) | 2010-08-04 | 2010-08-04 | Novel compounds for use in the treatment of Clostridium Difficile and associated diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201013058D0 true GB201013058D0 (en) | 2010-09-15 |
GB2482501A GB2482501A (en) | 2012-02-08 |
Family
ID=42799544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1013058.1A Withdrawn GB2482501A (en) | 2010-08-04 | 2010-08-04 | Novel compounds for use in the treatment of Clostridium Difficile and associated diseases |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2482501A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
SG10201400235PA (en) * | 2009-02-27 | 2014-07-30 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
CA2763140A1 (en) * | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
-
2010
- 2010-08-04 GB GB1013058.1A patent/GB2482501A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2482501A (en) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201403795B (en) | Formulations for the treatment of diabetes | |
HRP20160397T1 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
EP2544686A4 (en) | Combination methods for treatment of disease | |
EP2536436A4 (en) | Antimir-451 for the treatment of polycythemias | |
EP2596007A4 (en) | Process for the preparation of 17-desoxy-corticosteroids | |
IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
ZA201300546B (en) | Process for the preparation of 3-haloalkylpyrazoles | |
PT2593423E (en) | Process for the preparation of contrast agents | |
GB201013060D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
PT2390246T (en) | Process for the preparation of aminaphtone | |
GB201013058D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201009085D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201009108D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201009090D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201009091D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
GB201009104D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201009081D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
PT2598504E (en) | Process for the preparation of dimiracetam | |
GB201106968D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201106985D0 (en) | Compounds for the treatment of clostridium difficile associated disease | |
GB201106970D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
GB201106972D0 (en) | Compounds for the treatment of clostridium difficile-associated disease | |
GB201009097D0 (en) | Compounds for the treatment of clostridium difficile-associated disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |